Use of ramipril in preventing stroke: Double blind randomised trial

British Medical Journal

Volumn 324, Issue 7339, 2002, Pages 699-702

  Bosch, Jackie ^a   Yusuf, Salim ^a   Pogue, Janice ^a   Sleight, Peter ^b   Lonn, Eva ^a   Rangoonwala, Badrudin ^c   Davies, Richard ^d   Ostergren, Jan ^e   Probstfield, Jeff ^f  

^a MCMASTER UNIVERSITY   (Canada)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c University of Ottawa Heart Institute ^*  (Germany)

^d UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^e KAROLINSKA INSTITUTE   (Sweden)

^f UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; PLACEBO; RAMIPRIL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COGNITION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STATISTICAL ANALYSIS; STROKE; TRANSIENT ISCHEMIC ATTACK; VASCULAR DISEASE;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CEREBROVASCULAR ACCIDENT; COGNITION; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MIDDLE AGED; RAMIPRIL;

EID: 0037160928     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Alternative projections of mortality and disability by cause 1990-2020: Global burden of disease study
2. American Heart Association Prevention Conference IV: Prevention and rehabilitation of stroke, executive summary
3. Primary prevention of ischemic stroke: A statement for healthcare professionals from the stroke council of the American Heart Association
4. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context
5. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
6. Salt and hypertension
7. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection
8. The HOPE (heart outcomes prevention evaluation) study: The design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events
9. Vitamin E supplementation and cardiovascular event in a high-risk population
10. Nonparametric estimation from incomplete observations
11. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
12. Effects of ramipril and vitamin E on atherosclerosis: The study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE)
13. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective observational study
14. PROGRESS (perindopril protection against recurrent stroke study): Rationale and design
15. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack